Here, the researchers undertake a double-blinded, double-dummy randomized controlled non-inferiority trial to compare sublingual misoprostol and intramuscular oxytocin for the prevention of postpartum hemorrhage in Uganda, a country where there are more than 5,500 maternal deaths every year. The gene discussed is OXT; the disease is postpartum hemorrhage.